Whalesbook
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has completed its Phase 3 trial for BP11, an omalizumab biosimilar aimed at competing with the drug Xolair. The study included 608 patients at nearly 80 sites in Europe and India. It met its primary goals, showing similar effectiveness and safety to Xolair, especially in patients with chronic spontaneous urticaria (CSU) receiving a 300 mg dose. This milestone supports the company's plan to submit applications to the EMA and FDA by the end of the second quarter of 2026. The announcement led to a small 0.5% rise in Aurobindo Pharma's stock, which closed at ₹1,340.2 on the NSE. The company’s market capitalization is around ₹77,534 crore with a P/E ratio of about 22x.
The global biosimilar market is expanding rapidly, expected to grow from about $38.67 billion in 2026 to $138.60 billion by 2034. This growth is fueled by patent expiries of major biologic drugs and a higher demand for more affordable treatments. Aurobindo's BP11 targets indications such as CSU, allergic asthma, and chronic rhinosinusitis with nasal polyps, where Xolair holds a large market share, earning roughly $3.9 billion in US sales in the year ending April 2025. Other companies are also active in this space. Celltrion's Omlyclo was approved by the FDA in March 2025 and is considered interchangeable in the US. Teva Pharmaceuticals had its omalizumab biosimilar filings accepted by the FDA and EMA by April 1, 2026. Amneal, with Kashiv BioSciences, plans a BLA submission in Q4 2025. Aurobindo's planned Q2 2026 filing positions it in this competitive landscape, where speed to market and patient access are key. Aurobindo Pharma's stock has shown resilience, recently hitting 52-week highs, supported by sector strength and analyst upgrades, with most analysts rating it a 'Moderate Buy' and setting a 12-month price target around ₹1,385.
Despite the successful trial results, Aurobindo Pharma faces notable challenges for BP11. The company has been under US FDA scrutiny. In February 2026, FDA reports listed nine serious observations at its Unit 7 facility in Telangana, concerning sanitation, cross-contamination, and data integrity. These regulatory issues have previously affected its stock price and could delay or block approvals for new products like BP11. The market for omalizumab biosimilars is highly competitive, with Celltrion and Teva already making regulatory progress. Xolair's market is expected to shrink significantly, from $3.7 billion in 2023 to $1.6 billion by 2029, indicating price competition. Gaining market share will demand strong commercial efforts and potentially lower profit margins. Aurobindo's recent financial results show slower profit and sales growth compared to industry averages, making a successful market entry crucial. Furthermore, the US FDA classified Unit-V of its subsidiary Apitoria Pharma as voluntary action indicated in March 2026.
Aurobindo Pharma is focusing on expanding its product pipeline into complex generics and biosimilars, and is entering biologics contract manufacturing through Engenra Biologics to diversify its income. The planned regulatory submissions for BP11 by mid-2026 are a significant step toward making affordable omalizumab treatments more widely available for various conditions. BP11's success will rely on securing timely regulatory approvals, gaining market share against strong rivals, and adapting to changing prices in the biosimilar market, while also addressing past regulatory concerns. Analysts generally view the company positively, with most recommending 'Buy' or 'Outperform' ratings and expecting ongoing growth from its research and development efforts.